- Nachrichtendetail
-
19.06.2024 07:26:12 - dpa-AFX: AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis
WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Wednesday said the Food and Drug
Administration (FDA) has approved Skyrizi for the treatment of ulcerative
colitis.
The approval was based on two Phase 3 studies dubbed INSPIRE and COMMAND, in
which primary endpoint of clinical remission was achieved along with endoscopic
improvement, a key secondary endpoint.
Skyrizi is already approved in the U.S. for plaque psoriasis, psoriatic
arthritis, and Crohn's disease.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Administration (FDA) has approved Skyrizi for the treatment of ulcerative
colitis.
The approval was based on two Phase 3 studies dubbed INSPIRE and COMMAND, in
which primary endpoint of clinical remission was achieved along with endoscopic
improvement, a key secondary endpoint.
Skyrizi is already approved in the U.S. for plaque psoriasis, psoriatic
arthritis, and Crohn's disease.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ABBVIE | A1J84E | NYSE | 168,990 | 27.06.24 22:00:46 | -2,160 | -1,26% | 168,310 | 169,950 | 170,710 | 171,150 |
